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Clinical relevant dissolution specification
Food effect
A B S T R A C T
Background: Zolpidem is a non-benzodiazepine hypnotic agent which has been shown to be effective in inducing
and maintaining sleep in adults and is one of the most frequently prescribed hypnotics in the world. For drugs
that are used to treat sleeping disorders, the time to reach the maximum concentration (Tmax) of the drug in
plasma is important to achieving a fast onset of action and this must be maintained when switching from one
product to another.
Objectives: The main objective of the present work was to create a PBPK/PD model for zolpidem and establish a
clinically relevant “safe space” for dissolution of zolpidem from the commercial immediate release (IR) for-
mulation. A second objective was to analyze literature pharmacokinetic data to verify the negative food effect
ascribed to zolpidem and consider its ramifications in terms of the “safe space” for dissolution.
Methods: Using dissolution, pharmacokinetic and pharmacodynamic data, an integrated PBPK/PD model for
immediate release zolpidem tablets was constructed in Simcyp®. This model was used to identify the clinically
relevant dissolution specifications necessary to ensure efficacy.
Results: According to the simulations, as long as 85% of the drug is released in 45 minutes or less, the impact on
the PK and PD profiles of zolpidem would be minimal. According to the FDA, the drug has to dissolve from the
test and reference products at a similar rate and to an extent of 85% in not more than 30 minutes to pass
bioequivalence via the BCS-biowaiver test. Thus, the BCS-biowaiver specifications are somewhat more stringent
than the “safe space” based on the PBPK/PD model. Published data from fasted and fed state pharmacokinetic
studies suggest but do not prove a negative food effect of zolpidem.
Conclusions: A PBPK/PD model indicates that current BCS-biowaiver criteria are more restrictive for immediate
release zolpidem tablets than they need to be. In view of the close relationship between PK and PD, it remains
advisable to avoid taking zolpidem tablets with or immediately after a meal, as indicated by the Stilnox® la-
beling.
Introduction
Zolpidem is a non-benzodiazepine hypnotic agent which has been
shown to be effective in inducing and maintaining sleep in adults and is
one of the most frequently prescribed hypnotics in the world
(Norman et al., 2017; Salvà and Costa, 1995). Factors contributing to its
success are the rapid absorption of zolpidem after oral ingestion, which
facilitates rapid induction of sleep, and the short elimination half-life
(2.4h), which leads to fewer residual (“hangover”) effects compared
with other options used for sleep induction (de Haas et al., 2010;
Vermeeren, 2004).
The mechanism of action of this imidazopyridine comprises inter-
actions at the benzodiazepine ω1-receptor subtype, with its hypnotic-
sedative action exclusively attributable to agonist binding to the α1-
gamma-aminobutyric acid type A (GABAA) receptors. The α1-GABA
receptor is essentially associated with sedation, whereas other receptor
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subtypes are responsible for the various further effects of GABAergic
ligands, such as muscle relaxation, anxiolytics and amnesia (de Haas
et al., 2010). The selectivity of zolpidem's binding explains why it has a
strong sedative effect, but only minor activity as an anxiolytic, myor-
elaxant and anticonvulsant (Salvà and Costa, 1995).
For drugs that are used as hypnotics to treat sleeping disorders, the
time to reach the maximum concentration (Tmax) of the drug in plasma
is important to achieving a fast onset of action (Greenblatt, 2010). As
food intake can delay the gastric emptying time and thus the absorption
of drugs with short half-lives, such as zolpidem, the rate and potentially
the extent of drug absorption can be reduced if administered in the fed
state, leading to treatment failure (Eller and Della-Coletta, 1990;
Greenblatt et al., 1978; Locniskar et al., 1984; Ms et al., 2007). Notably
for zolpidem, the labeling of the commercial product describes zol-
pidem as having a negative food effect. This applies to the immediate
release (IR), modified release (MR) and sublingual (SL) formulations of
zolpidem (Andreas et al., 2017; FDA, 2007 ; Paraiso et al., 2019).
In general, dissolution tests on oral drug products are performed
with media that are described in the pharmacopeia. These tests are
often used in the development of drug products containing highly so-
luble drugs to guide the formulation process and in quality control
testing of the commercial product (Tsume et al., 2018). For poorly so-
luble drugs, biorelevant dissolution media which simulate the compo-
sition of gastrointestinal environment fluids are often more appropriate
(Fotaki and Vertzoni, 2010; Jantratid et al., 2009; Klein, 2010;
Markopoulos et al., 2015). Biorelevant media have also been applied to
set clinically relevant dissolution specifications (CRDS) and to establish
a dissolution “safe space” for drug formulations. To set CRDS, the ac-
ceptance criteria for the in vitro dissolution test must be linked to the in
vivo performance of drug formulation (Hermans et al., 2017; Dickinson
et al., 2008; Tsume et al., 2018). However, establishing this relationship
between dissolution performance and in vivo results is not always
straightforward.
Recent advances in physiologically based pharmacokinetic (PBPK)
modeling with different commercial platforms available in the market
has facilitated the translation of in vitro dissolution data into predictions
of the in vivo plasma profile of drugs to set the CRDS (Hermans et al.,
2017; Tsume et al., 2018). Going one step further, it is also possible to
couple PBPK platforms with pharmacodynamic (PD) models. Using this
approach, there is a possibility to integrate dissolution data into the
PBPK model and couple it with the PD model to establish a truly
clinically driven “safe space” for the dissolution of the drug formulation
(Cristofoletti and Dressman, 2014).
The main objective of the present work was to create a PBPK/PD
model for zolpidem in Simcyp® and establish a safe space for the dis-
solution of zolpidem from the commercial immediate release (IR) for-
mulation using dissolution, pharmacokinetic and pharmacodynamic
data. According to the Biopharmaceutical Classification System (BCS)
proposed by Amidon and co-workers (1995) zolpidem is a member of
BCS class I, being characterized as a highly soluble and highly perme-
able weakly basic compound with a pKa of 6.16 (Amidon et al., 1995;
Colo et al., 2015; Ramirez et al., 2010). Further, since zolpidem (IR) has
been described as having a negative food effect, the impact of time of
dosing on PK/PD outcomes was also explored.
2. Material and methods
2.1. Materials
The zolpidem dissolution profiles used to build the PBPK/PD model
was performed with Stilnox® tablets (Batch No. #70662; Sanofi-
Aventis, Gentilly, France). The in vitro dissolution profiles of Stilnox®
tablets were obtained from Paraiso and co-workers (2019).
2.2. Biorelevant dissolution tests
Although as a BCS Class I drug, compendial media would be ap-
propriate for studying dissolution of zolpidem in the fasted state, to
simulate the food effect in vitro it is necessary to use biorelevant media
(Markopoulos et al., 2015). Data for biorelevant dissolution simulating
the fasted and fed states were taken from a previous publication by
Paraiso and co-workers (2019) (Paraiso et al., 2019). The data were
digitized using the software WebPlotDigitizer v. 4.2 (San Francisco,
USA; source: https://automeris.io/WebPlotDigitizer). The composition
of the biorelevant media used to simulate the fed state is summarized in
Table 1. The biorelevant dissolution tests were performed using USP 2
dissolution test apparatus (Erweka DT 80, Heusenstamm, Germany) at
37± 0.5o C in 500 mL medium. The dissolution behavior of Stilnox®
tablets was investigated at 50 rpm in 500 mL of FeSSGFmiddle Level II,
and in FeSSIF-V2 Level II (pH 5.8). FeSSGFmiddle (pH 5.0 and 1.75% fat)
is the biorelevant media that represents the period from 75-165 minutes
after food ingestion. This medium was selected because in the clinical
study, Stilnox® tablets were ingested after a low fat breakfast
(Greenblatt et al., 2006). Sampling for all dissolution tests was per-
formed at 5, 10, 20, 30, 40, 50, 60 and 120 minutes.
2.3. PBPK model
The PBPK model was built using the Simcyp® Simulator (V18.1;
Certara, Sheffield, UK). Zolpidem parameters inputted into the PBPK
model are shown in Table 2. The required data regarding drug physi-
cochemical and pharmacokinetic properties were obtained from the
literature sources cited in the table.
To best describe the pre-absorptive processes, i.e. drug dissolution
in the gastrointestinal tract, the advanced dissolution, absorption and
metabolism (ADAM) module was used. The framework of the ADAM
module has already been described in the literature (Cristofoletti and
Dressman, 2014; Darwich et al., 2010; Jamei et al., 2009). There are
different ways to input dissolution data into this module. The first
possibility is to input the dissolution profiles simulating the gastric and
small intestine environment directly into the platform, the second is to
use a Weibull function to fit the data and the third is to insert the so-
lubility and dissolution data into the diffusion layer model (DLM)
function. In this work we used the first option, inserting the dissolution
profile directly into the respective gastrointestinal segments. Thus, the
dissolution profiles were entered separately into the stomach (results in
FeSSGFmiddle) and the small intestine (results in FeSSIF-V2) segments
using the piecewise cubic polynomial approach as the interpolation
Table 1
Composition and physicochemical characteristics of Level II biorelevant media
for simulating the environment of gastric and the small intestine after a low fat
meal.
Gastrointestinal segment Stomach Small Intestine
(proximal)
Biorelevant media Level II -
FeSSGFmiddle
Level II - FeSSIF V2
Acetic acid (mM) 18.31 -
Sodium acetate (mM) 32.98 -
Maleic acid (mM) - 71.9
Sodium hydroxide (mM) - 102.4
Lipofundin / buffer 8.75: 91.25 -
Sodium taurocholate (mM) - 10
Lecithin (mM) - 2
Glyceryl monooleate (MmM) - 5
Sodium oleate (mM) - 0.8
Sodium chloride (mM) 181.7 125.5
Osmolality (mOsm/kg) 400 390
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method.
Since zolpidem has a low to moderate volume of distribution (Vss)
with a value of 0.54 L/kg, the minimal PBPK model was applied to
predict the plasma profile of this drug. Additionally, the unbound
fraction of 8% in plasma, which was reported by Durand and co-
workers (1992), was applied in the model (Durand et al., 1992).
To predict the elimination phase of the drug, the oral clearance data
reported by Greenblatt and co-workers (2006) were used. For healthy
adults the renal clearance (CLR) was 0.18 (L/h) (Greenblatt et al.,
2006).
2.3.1. Clinical study
In the clinical studies realized by Greenblatt and co-workers (2006)
zolpidem immediate release tablets were administered to men and
women two hours after intake of a light breakfast (Greenblatt et al.,
2006). These conditions were modeled in Simcyp® by running simula-
tions in a “healthy volunteer” cohort with the same gender ratio and
age as the study cohort, in which the gastrointestinal physiology was
adapted to represent conditions after ingestion of a low fat meal.
2.3.2. Verification of the PBPK model using an internal PK data set
The parameters and conditions of the trials depicted in Table 2 were
used to build the PBPK model. The validation of the PBPK/PD model for
this drug was done using an internal validation approach adopting the
pharmacokinetic and pharmacodynamic in vivo data from Greenblatt
and co-workers (2006). It was not possible to use external data to va-
lidate the method since no other studies using similar trial conditions
(men and women, light breakfast) could be found in the open literature.
2.4. PD model
2.4.1. Percentage of β-EEG variation
To evaluate the hypnotic effect of drugs, different measures are
described in the literature. Some of them are considered subjective e.g.
observationally rated sedation, self-rated sedation, digit symbol sub-
stitution test (DSST), while others are more objective e.g. variations in
α, β and γ brain waves (Cysneiros et al., 2007; de Haas et al., 2010;
Drover et al., 2000; Greenblatt et al., 2006, 1998).
Since the % change in the β-EEG amplitude is objective and is the
outcome most often used to describe the hypnotic effects of zolpidem,
we used this pharmacodynamic parameter to build the PD model.
Results for % change in β-EEG were taken from a published PK/PD
study that was used to compare the kinetics and dynamics of zolpidem
IR with the modified release (MR) formulation. This study was con-
ducted with 70 male and female healthy volunteers with 46% women
enrolled (Greenblatt et al., 2006). Since the time to reach the maximum
drug concentration in plasma (Tmax) and the time to reach the max-
imum pharmacological response (TRmax), together with maximum
plasma concentration (Cmax) and the maximal response (Rmax), showed
an almost linear correlation, with no hysteresis (Fig. 1), the authors
concluded that the % change in the β-EEG profile after treatment with
zolpidem would be well described by a single exponential equation:
=y xm (1)
For this reason, we used the power function model (the default
model in the software) to develop the PD model in Simcyp®. The power
function model is represented by the following equation:
= +R E PKInput1 ·( )m0 (2)
where R1 is the pharmacological response, E0 is the initial % change in
the β EEG wave (in our model E0=0), α is a linear coefficient,
PKInput is the plasma profile concentration entered for time t, and m is
the exponential coefficient of the equation. The in vivo data obtained
from Greenblatt and co-workers (2006) were used to estimate the α and
m parameters of the model (Greenblatt et al., 2006).
Table 2
Parameters used to implement the zolpidem PBPK model (Simcyp Simulator®V18.1).
Parameters Value Reference/Comments
Molecular weight (g/mol) 307.39 Salvà and Costa, 1995
Log P 2.42 Salvà and Costa, 1995
Compound type Monoprotic base Salvà and Costa, 1995
pKa 6.16 Salvà and Costa, 1995
Absorption (low fat fed model) ADAM model
Dissolution level II FeSSGFmiddle Dissolution profile Paraiso et al., 2019
Dissolution level II FeSSIF-V2 Dissolution profile Paraiso et al., 2019
Peff 6.5 × 10−4 cm/s Andreas et al., 2017b
Absorption (fasted model) ADAM model
Dissolution level II FaSSGF Dissolution profile Paraiso et al., 2019
Dissolution level II FaSSIF-V2 Dissolution profile Paraiso et al., 2019
Peff 6.5 × 10−4 cm/s Andreas et al., 2017b
Distribution Minimal PBPK model
Main binding protein albumin Salvà and Costa, 1995
Vss (L/kg) 0.54 Durand et al., 1992
Fu gut 0.035 predicted using Simcyp®
Blood to plasma coefficient (B:P) 0.76 Salvà and Costa, 1995
Fu plasma 0.08 Durand et al., 1992
Elimination
Oral clearance (L/h) 16.56 Greenblatt et al., 2006a
CLR (renal clearance) (L/h) 0.18 Simcyp® default
PD model Power function
Exponent (m) 1.17 Estimated form Greenblatt et al., 2006a




Formulation option in the software Immediate release (IR) with interpolation of the observed in vitro dissolution data. Default setting in Simcyp®
Population modeling Virtual population trials were conducted using 700 (70 × 10) male and female healthy
volunteers, age ranged 18-45 years for each study.
Greenblatt et al., 2006a
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2.5. PK/PD simulations
Simcyp Simulator® version 18.1 was used to predict the plasma
concentration and the % change in the β wave by zolpidem. The virtual
population was selected to closely match the population enrolled by
Greenblatt and co-workers (2006) with regard to age range and gender
ratio (Greenblatt et al., 2006). The virtual trials simulating the “low fat”
fed state were performed on the basis of administering zolpidem IR
tablets with 250 mL of water 2 hours after a light breakfast. Starting
with the intake of the drug, the clinical trial was conducted over 12 h.
The following simulations were performed:
- To evaluate the hypnotic effect of zolpidem using the % change in
the β-waves, a virtual trial was conducted enrolling 70 adults aging
19–45 years (46% females) receiving a single oral dose of 10 mg zol-
pidem administered as the IR tablet. The predicted data were compared
with the observed data to internally verify the model, as no other
publication with a similar trial design could be located in the open
literature.
- To determine the key parameters in the PBPK/PD model, a sen-
sitivity analysis was performed. The effect of two different input vari-
ables on the PK and PD responses of zolpidem was evaluated using the
‘one-at-a-time’ variation approach. Gastric emptying time (GET) (with
values ranging from 0.4 to 2.0 h) and effective permeability (Peff) (with
values ranging from 4 to 8 × 10−4 cm/s) were the two variables tested.
- To set clinically relevant dissolution specification for zolpidem IR
tablets, the model developed for zolpidem administered after a low fat
meal was extrapolated to the fasted state. In order to simulate the
plasma profile and the % change in β-EEG amplitude in the fasted state,
the same structural model as used for the low fat fed state was applied.
All parameters (Table 2) were kept constant, with the exceptions that
the dissolution under conditions representing the fasted state and the
default values in Simcyp® for the healthy population in the fasted state
were applied. After the simulation in the fasted condition was gener-
ated, the plasma profile was verified with external data from Weinling
and co-workers (2006) (Weinling et al., 2006b). This study was con-
ducted in 24 healthy male volunteers, age range 18-45 years, under
fasting conditions. The volunteers received 10 mg zolpidem hemi-
tartarate IR tablets in a cross-over design. . After constructing and
verifying this scenario, different dissolution rates in a fasted state
medium adjusted to pH 6.8 (ranging from 85% dissolved in 15 min to
85% dissolved in 120 min) were simulated and then entered into the
model to generate the PK and PD responses of zolpidem under these
conditions. These simulations were conducted in 10 virtual trials, each
enrolling 70 adults aged 18–40 years and receiving a dose of 10 mg of
zolpidem IR tablets on an empty stomach.
Fig. 1. Relationship between mean plasma zolpidem concentration and mean
changes in the percentage electroencephalographic (EEG) of β brain waves at
corresponding times. Arrows indicate the direction of increasing time.
Reproduced with permission from Greenblatt and co-workers (2006).
Fig. 2. PBPK/PD model strategy for zolpidem immediate release tablets
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A schematic of the steps used to create the models is shown in Fig. 2.
2.6. Data presentation and statistical analysis
The simulated (predicted) plasma profiles using Simcyp® software
were compared with in vivo data (observed) using the average fold error
(AFE) and absolute average fold error (AAFE) (Obach et al., 1997;






where n is the numbe r of time points at which the concentration was
obtained, predictedi and observedi are the predicted and observed
concentrations at a given time point i. The average fold error indicates
whether the predicted profile underestimates or overestimates the ob-
served values (as shown in Eq. 3): if the AFE value is less than 1 there is
an underestimation and if the AFE value is greater than 1 there is an
overestimation of the observed value.
The absolute average fold error quantifies the absolute error from
the true value (as shown in Eq. 4). If AAFE ≤ 2, the simulation is








3.1. Development and verification of the PBPK/PD model of zolpidem
Fig. 3 depicts the dissolution profiles of 10 mg Stilnox® immediate
release tablets in biorelevant media simulating the gastric (FeS-
SGFmiddle) and upper intestinal (FeSSIF-V2) environment after ingesting
a low fat meal (Paraiso et al., 2019). This figure shows that there were
only small differences in the rate and extent of dissolution comparing
the gastric (lower) and intestine environment (higher).
In order to simulate the “low fat” fed state plasma and pharmaco-
dynamic profile of zolpidem, the dissolution profiles simulating the
gastric and small intestine were inputted into the PBPK/PD model in
Simcyp® together with drug properties and pharmacokinetics para-
meters listed in Table 2.
Fig. 4 depicts the simulated and observed mean zolpidem plasma
concentration and mean % change in the β-waves profiles together with
the predicted 5th and 95th percentiles around the means.
Table 3 summarizes the calculated PK parameters (Tmax, Cmax and
AUC), along with AFE and AAFE values. The results indicate that dis-
solution profiles obtained with FeSSGFmiddle and FeSSIF-V2 combined
with the PBPK model were able to predict the in vivo behavior of zol-
pidem IR tablets. The AFE for the simulation was 1.07 and the AAFE
was 1.10, indicating that the developed model predicted the plasma
profile of zolpidem accurately.
Table 4 reports the simulated and observed PD parameters for zol-
pidem. As for the PK parameters, the simulated PD parameters (Rmax
and AUCR and TRmax) were very close to those obtained in the in vivo
study. The AFE was 1.11 and the AAFE was 1.13, indicating that the
developed model was able to closely predict the pharmacodynamic as
well as the pharmacokinetic profile of the drug.
Fig. 5 depicts the relationship between plasma concentration and
pharmacodynamic response for zolpidem. The relationship between PK
and PD has r2 of 0.9969, indicating the excellent correlation between
the plasma concentration of the drug and the PD response.
3.1.1. Parameter sensitivity analysis (PSA) to determine the effect of gastric
emptying time (GET) and effective permeability (Peff x10−4) on the
zolpidem PK profile
After developing and validating the PBPK/PD for zolpidem, a
parameter sensitivity analysis (PSA) was conducted to determine which
parameters could be important to establish the plasma profile and or PD
response for zolpidem. Since the pharmacodynamic response is linearly
related to the pharmacokinetics, the pharmacodynamic profiles are not
shown.
Fig. 6a depicts how the plasma profile of zolpidem changes as a
function of gastric emptying. Sensitivity analysis demonstrated that at
longer gastric emptying times the in vivo Cmax and AUC were under-
predicted and the Tmax was longer. The simulations came closest to the
observed mean Cmax when a GET between 0.8 and 1.0 h was applied,
and the Tmax was best simulated by a GET of 0.9 h. These results suggest
that GET may play a role in zolpidem absorption and thus onset of
action of zolpidem. By contrast, Peff (Fig. 6b) did not change the PK
profiles significantly over the range tested.
3.2. Dissolution profile to generate the clinical relevance of dissolution for
zolpidem
Fig. 7 depicts the dissolution profile of 10 mg Stilnox® immediate
release tablets in biorelevant media simulating the gastric (FaSSGF) and
upper intestinal (FaSSIF-V2) environment in the fasted state taken from
Paraiso and co-workers (2019) (Paraiso et al., 2019). This figure shows
that there is no difference in the rate and extent of dissolution between
the simulated gastric and small intestine environments.
After developing and validating the PBPK/PD model to represent
the fed state after a low fat meal, it was extrapolated to the fasted state.
Fig. 8 depicts the simulated plasma profile together with the in vivo data
obtained from Weinling and co-workers (2006) (Weinling et al.,
2006b). The PD profile could not be verified externally because no in
vivo data for % change in β-EEG under fasted state conditions is
available in the open literature.
As previously mentioned, zolpidem belongs to BCS class I. Its so-
lubility is not affected by pH within the range found in the stomach and
upper small intestine (pH 1.2 to 6.8). In light of these characteristics,
the clinical relevant dissolution specification for zolpidem was eval-
uated by simulating different dissolution rates at pH 6.8 (Fig. 9), ran-
ging from 85% dissolved in 15 min to 85% dissolved in 120 min. These
simulated fasted state dissolution profiles were then entered as the
small intestinal dissolution profile in the ADAM module. The results for
the PK and PD responses of zolpidem using the Simcyp® model outputs
are depicted in Fig. 10.
Fig. 10 shows the pharmacokinetic and pharmacodynamic para-
meters values obtained after inputting the simulated dissolution profile
into the PBPK/PD model in fasted state for zolpidem. On the one hand
the results suggest that different dissolution rates would affect the
magnitude of AUC0–12h, AUCR, Cmax, and Rmax values by less than 10%
when Q ≥ 85% in 15, 30 or 45 min. On the other hand, when slowly
Fig. 3. Mean dissolution profiles of 10 mg immediate release Stilnox® tablets in
biorelevant Level II dissolution media simulating the low fat fed state using USP
apparatus II. Reproduced with permission from Paraiso et. al (2019).
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dissolving tablets with Q ≥ 85% in 60 min were simulated, the Tmax
and TRmax were delayed to 1.7 h, which translates into an expected
delay in the onset of hypnotic effect compared with the response eli-
cited by simulating the case of very rapidly dissolving tablets, Q ≥ 85%
in 15 minutes. Therefore, the results suggest that only in the case of
tablets with a slow dissolution of Q ≥ 85% in 60 minutes or more
would lead to clinically significant changes in the time at which the
maximum PK and PD responses are observed.
3.3. Survey of clinical studies in the literature on the negative food effect for
zolpidem immediate release tablets
In the commercial label of Stilnox® 10 mg IR tablets and in previous
publications, zolpidem is described as having a negative food effect
(Andreas et al., 2017; Greenblatt et al., 2013). Paraiso and co-
workers (2019) published the mean plasma profile of the food effect
investigation leading to this labeling and noted that the subject cohort
consisted of 30 healthy male volunteers rather than a mixed-gender
group (Paraiso et al., 2019).
Fig. 11a shows the mean plasma profile of zolpidem when ad-
ministered in fasted and fed state. In that study, the coefficients of
variation (CV) for PK Tmax, Cmax and AUC were tabulated, but varia-
tions at individual time points were not reported.
According to the mean profiles, lower values for both AUC and Cmax
as well as a 60% prolongation in Tmax were observed in the fed com-
pared to the fasted state for zolpidem IR. In both states, the results
showed high CVs for all pharmacokinetic parameters: in the fasted state
the CV for Cmax 42% and for AUC 56 %, while in the fed state, Cmax
showed a 43 % CV and AUC showed a 52 % CV. The fed/fasted ratios
for AUC and Cmax were 0.86 and 0.76, respectively, indicating that in
the fed state, AUC and Cmax were decreased on the average by ~15%
and 25%, respectively, compared to the fasted state, suggesting a ne-
gative food effect (Paraiso et al., 2019).
The PBPK model we developed for zolpidem IR also suggests that in
the fed state Cmax and AUC would be somewhat decreased and the Tmax
prolonged (Fig. 11b and c). Another important aspect is that the si-
mulations captured the high inter-individual variability in the zolpidem
plasma profile in both prandial states well.
To better understand the food effect, a literature search was con-
ducted to locate publications of zolpidem IR clinical trials that had been
conducted under fasted or fed conditions and compare their pharma-
cokinetic parameters (Cmax and AUC). A total of 13 studies were lo-
cated, 9 of which had been conducted in the fasted state and 4 in the fed
state. In Fig. 12 the values of Cmax, AUC and Tmax for these trials are
depicted.
Studies listed in the Figure 12
1 Weinling et al., 2006. Study in male healthy volunteers.
2 Stilnox® – FDA label food effect study, 1992. Fasted state arm (Male healthy
volunteers).
3 Zolpidem - Public Assessment Report Netherlands, 2010. Study with male
healthy volunteers.
Fig. 4. (a) Mean observed (●) and model predicted PK profile (solid line) for health adults after administration of zolpidem IR tablets in the “low fed state”. (b) Mean
observed (●) and model predicted PD profile (solid line) after administration of zolpidem IR tablets over time.
Table 3
Pharmacokinetic parameters obtained in the clinical trial of zolpidem with the
outcomes from simulations using in vitro data inputted from biorelevant dis-
solution tests simulating the fed state after a low fat meal.
PK parameter Simulated Observed % difference AFE/AAFE
Cmax (ng/mL) 107.47 108.85 -1.26 -
AUC0-12 (ng.h/mL) 577.23 565.78 -1.98 -
Tmax (h) 2.00 2.02 0.02 -
AFE - - - 1.07
AAFE - - - 1.10
Table 4
Zolpidem pharmacodynamic parameters obtained in the study with the corre-
sponding simulation results using in vitro data input from biorelevant dissolu-
tion tests simulating the fed state after a low fat meal.
PD parameter Simulated Observed % difference AFE/AAFE
Rmax 6.22 6.35 -2.05
AUCR0-12 (ng.h/mL) 30.08 30.01 -0.7
TRmax (h) 2.12 2.0 0.12
AFE - - - 1.11
AAFE - - - 1.13
Fig. 5. Relationship between mean values of plasma concentration versus PD
response of zolpidem.
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4 Park et al., 2011. Study in male healthy volunteers.
5 Stilnox® – FDA - Label food effect study 1992. Fasted arm (male and female
healthy volunteers).
6 Public Assessment Report Netherland - Zolpidem Tartraat Aurobindo, 2018.
Study with male healthy volunteers.
7 Galitz et al., 2015. Study in male and female healthy volunteers.
8 Durand et al., 1992. Study in male healthy volunteers.
9 Allard et al., 1998. Study in female healthy volunteers.
10 Stilnox® - FDA - Label food effect study 1992. Fed state arm (Male healthy
volunteers, compare with Study 2)
11 Greenblatt et al., 1998. Study in male healthy volunteers.
12 Greenblatt et al., 2000. Study in male and female healthy volunteers.
13 Greenblatt et al., 2006. Study in male and female healthy volunteers.
In these studies, the average (mean) values for Cmax and AUC in the
fed state tended to be lower than in the fasted state, while the Tmax was
mostly prolonged in the fed state compared to the fasted state.
However, there is some overlap in the pharmacokinetic parameters
between the fed and fasted states.
4. Discussion
4.1. Clinically relevant dissolution specifications for zolpidem IR products
To arrive at clinically relevant dissolution specifications, it is im-
portant to establish a relationship between in vitro experiments and in
vivo studies. Although there is large variability in the gastrointestinal
physiology among volunteers/patients and thus challenges in estab-
lishing relationships between in vitro and in vivo data, biorelevant dis-
solution and PBPK modeling platforms provide an important way for-
ward to establishing such relationships (Hermans et al., 2017;
Markopoulos et al., 2015; Tsume et al., 2018). Drugs belonging to BCS
class I and III in products with fast/very rapid dissolution are con-
sidered low risk products, for which there is generally no need to es-
tablish an in vitro/in vivo correlation (IVIVC) (Hermans et al., 2017;
Polli et al., 2008; Tsume et al., 2018). Although zolpidem is a BCS class
I, it has a short half-life, which most probably contributes to its clas-
sification as a highly variable drug when given orally. Further, for
hypnotic drugs like zolpidem a high exposure and rapid effect for
hypnotic drugs is usually desired. Therefore, for zolpidem in particular,
it is important to identify an in vitro/in vivo relationship in order to set
clinically relevant dissolution specifications.
Although standard IVIVC approaches are often used to set the CRDS,
zolpidem IR formulations are not amenable to classical Level A IVIVC.
For this reason, we used the alternative approach consisting of PBPK
modelling coupled with the PD response. This approach has the further
advantage of linking the CRDS all the way to the PD response, whereas
classical IVIVC stops at correlating the dissolution with the PK para-
meters. Dissolution media that can be used to set clinically relevant
dissolution specification for drug products can be anywhere between
Levels 0 and 3 in the classification according to Markopoulous and co-
workers (2015) Level 0 represents the simplest composition, attempting
to represent only the pH in a segment of the gastrointestinal tract. As
the Level increases, the composition becomes more complex
(Markopoulos et al., 2015). Since zolpidem belongs to BCS class I and
its dissolution is not affected by the gastrointestinal pH, theoretical
dissolution curves at pH 6.8 (Level 0) with different dissolution rates
(Fig. 9) were implemented into the PBPK/PD model to generate the
corresponding plasma profiles of this drug. As shown in the simulation
results (Fig. 10), it appears that the PK and PD parameters would only
be significantly impacted if the formulation has disintegration/dis-
solution issues corresponding to Q ≥ 85% being reached after more
than 45 minutes.
Further guidance from EMA, FDA and ICH describes the possibility
of waiving in vivo studies for drugs that belong to BCS class I and III.
With regard to dissolution performance, this biowaiver approach is
Fig. 6. Zolpidem pharmacokinetic profile applying PSA: (a) on GET and (b) on Peff in the fed state after a low fat meal.
Fig. 7. Mean dissolution profiles of 10 mg immediate release Stilnox® tablets in
biorelevant Level II dissolution media simulating the fasted state using USP
apparatus II. Error bars lie within the symbols in all cases. Reproduced with
permission from Paraiso et. al (2019).
Fig. 8. Simulated and observed mean plasma zolpidem concentrations after
simulation of zolpidem administration in the fasted state.
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Fig. 9. Simulated dissolution profile in pH 6.8 to determine the clinical relevant dissolution specification.
Fig. 10. Predicted dose-response after imputing the simulated dissolution profile into the PBPK/PD model of zolpidem. a, c and e represent the pharmacokinetic
parameters and b, d and f the pharmacodynamic parameters.
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possible when the drug product dissolves very rapidly, which means
that the tablets dissolve and release more than 85% of the labeled
amount of the drug within 15 minutes, or when the drug formulation
dissolves rapidly and releases 85% of the drug content within 30
minutes in compendial media at pH 1.2, pH 4.5, and pH 6.8 (EMA,
2014; FDA, 2017; ICH, 2018). Comparing these limits to the PK/PD
model for zolpidem IR tablets, suggests that the regulatory agencies
could be somewhat more flexible with regard to the biowaiver criteria
when zolpidem IR tablets are evaluated. According to the results ob-
tained in our simulations, as long as 85% of the drug is released in 45
minutes or less, the impact on the PK and PD profiles of zolpidem would
be minimal (<10%).
Although the number of publications using dissolution data in
conjunction with PBPK modeling and simulation has significantly in-
creased in the last years, attempts to extend simulations through to
clinical relevance by linking the results to a PD model have been few.
Cristofoletti and Dressman (2014) used a PBPK/PD model to demon-
strate that changes in pharmacokinetic parameters do not produce a
proportional change in the antipyretic and anti-inflammatory activity
of ibuprofen, such that even if two drug products are not bioequivalent
with each other, they may still be therapeutically equivalent. This si-
tuation arises when the drug (in this case ibuprofen) has a flat dose-
response relationship in the usual dosing range (Cristofoletti and
Dressman, 2014). More recently, AbbVie used a PBPK modelling ap-
proach to broaden the dissolution criteria for Orilissa® (elagolix) ta-
blets. According to the original specifications, two commercial batches
failed to meet the dissolution acceptance criteria. But using the ab-
sorption modelling approach, the company was able to demonstrate to
the FDA that even when the drug product releases the drug more slowly
than the specifications require, there is no clinically significant effect on
the exposure of the drug (“FDA Quality Asseessment for Elagolix Ta-
blets,” 2018). In a further example of using PBPK to set CRDS, Astra
Zeneca proposed specifications for the particle size and dissolution rate
of lesinurade from Zurampic® tablets that would ensure appropriate
clinical performance of each batch, by running virtual bioequivalence
trials in the Gastroplus PBPK platform (Pepin et al., 2016).
4.2. Studies regarding the negative food effect of zolpidem
Positive and negative food effects may be associated with the drug
itself, the formulation and/or the physiology of the human gastro-
intestinal tract. Physiological parameters in the gastrointestinal tract
e.g., gastric emptying time, release of bile salts and enzymes, gastro-
intestinal pH and splanchnic blood flow, are highly variable. Changes in
Fig. 11. a Mean plasma zolpidem concentration after oral administration of 10 mg immediate release Stilnox® in 30 male subjects under fasting and fed
conditions. (Reproduced with permission from Paraiso et al. (2019)). b and c. Simulated PK profiles in a virtual population of 70 healthy male and female volunteers
after intake of 10 mg zolpidem tablets. b fasted state and c fed state.
Fig. 12. Studies comparing the pharmacokinetic parameters of zolpidem when administered in the fasted and fed states. (a) Cmax, (b) AUC and (c) Tmax values.
Closed dots (●) represent studies in the fasted state and open dots (○) in the fed state. In Fig. 13 (a) and (b) the values are presented as the mean and SD, in Fig. 13 (c)
only by the average values.
R.L.M. Paraiso, et al. European Journal of Pharmaceutical Sciences 155 (2020) 105534
9
these parameters after a meal may alter the interaction the drug or
dosage form with the gastrointestinal fluids. This complex combination
of factors may lead to alterations in the luminal metabolism of drug, in
vivo dissolution from the drug product, degradation of the drug and/or
its absorption and thus a positive or negative food effect.
Attempts to describe the negative food effect observed for zolpidem
with respect to AUC and Cmax showed that an increase in the fat content
of the biorelevant media had little or no direct effect on the dissolution
of zolpidem, however the longer gastric emptying time associated with
a higher fat content could slow gastric emptying and thus indirectly
affect the absorption profile (Paraiso et al., 2019). Similarly, when
Andreas and co-workers (2017) tested the modified release formulation
of zolpidem, they concluded that the negative food effect of zolpidem is
associated with the delay in the gastric emptying time of the formula-
tion. Additionally, it was shown that the release of zolpidem for the
formulation can be influenced by high fat and/or protein content
(Andreas et al., 2017).
In the zolpidem studies depicted in Fig. 12, the variability of Cmax
and AUC was high in both the fasted and fed arms of the studies. These
results are consistent with the fact that gastric emptying can vary
widely among individuals, with the phase of the motility cycle in the
fasted state, and between the fed and fasted states. Since zolpidem is
highly soluble and permeable and has a short elimination half-life, the
limiting step for absorption for this drug may well be the gastric
emptying time (Andreas et al., 2017; Colo et al., 2015). For drugs with a
short half-life, the Cmax becomes more sensitive to differences in the
rate of gastric emptying and this sensitivity is exacerbated when solu-
bility and permeability are not rate-limiting to absorption. Thus, the PK
parameters of zolpidem, a BCS Class I substance, are particularly prone
to intra and inter-individual variability in the gastric emptying time
(Andreas et al., 2017; Markopoulos et al., 2015; Wagner et al., 2012).
Although data from the literature combine to suggest that the zolpidem
IR formulation has a negative food effect, the high variability in Tmax,
Cmax and AUC, the variability in the mean values from trial to trial and
the paucity of trials in the fed state do not allow a firm conclusion to be
reached. A larger crossover study in healthy men and women would be
necessary to confirm the negative food effect indicated on the label.
4.3. Administration of zolpidem in the fasted or fed state?
The human circadian cycle can be different for each individual,
therefore, the eating habits and bedtime can be specific for each person.
Nevertheless, in general practice nutritionists and doctors instruct the
patients to wait at least two to three hours between the last meal of the
day and bedtime. This interval additionally allows for better digestion,
preventing problems like heartburn at night and even insomnia
(de Castro, 2004; De Zwaan et al., 2003; Schenck, 2006; Zwaan et al.,
2006). Since zolpidem is used to sleep induction, it seems likely that
most patients would take the product in the fed state. The marginal
negative food effect could potentially decrease the effectiveness of the
drug, while the delay in Tmax may incur a greater risk of residual se-
dation when compared with the fasting state. These considerations are
in line with the product label, which indicates that for optimal effect
Stilnox® tablets should not be taken with or immediately after a meal.
5. Conclusions
With the continuing evolution of PBPK models, physiologically
based absorption modelling coupled with pharmacodynamics is emer-
ging as an alternative methodology for development of in vitro-in vivo
relationships. The integration of in vitro biorelevant dissolution with in
silico methods such as PBPK or PBPK/PD is a promising tool to set
clinically relevant dissolution specifications and thus link the lab to the
patient. In this work, clinically relevant dissolution specifications for
zolpidem immediate release products were set, showing that as long as
drug release can meet a specification of Q ≥ 85% in 45 minutes or less,
the product will have acceptable pharmacodynamic characteristics.
This result suggests that the BCS-based biowaiver specifications (Q ≥
85% in 30 minutes plus f2>50 or Q ≥ 85% in 15 minutes) could be
relaxed for zolpidem IR products and potentially for other BCS Class I
drugs with short half-lives.
The high inter-subject variability in the PK parameters in the fasted
and fed state suggest that for zolpidem IR products, absorption is lar-
gely determined by gastric emptying. The product label for zolpidem
states that, due to delays in the gastric emptying and the associated
lower Cmax and AUC, it is recommended that zolpidem IR tablets should
be taken in the fasted state for faster onset of effect and higher ex-
posure. However, a review of clinical studies from the open literature
casts some doubt on the negative food effect for this drug and to settle
this question, a crossover study in men and women should be con-
ducted.
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